The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Novel strategy to restore the activity of taxanes: A multicenter phase II study of combination therapy with taxanes and toremifene at 120 mg for advanced/recurrent breast cancer—Kinki Multidisciplinary Breast Oncology Group (KMBOG0612).
T. Nakayama
No relevant relationships to disclose
T. Arai
No relevant relationships to disclose
J. Yamamura
No relevant relationships to disclose
T. Morimoto
No relevant relationships to disclose
Y. Komoike
No relevant relationships to disclose
K. Yoshidome
No relevant relationships to disclose
S. Kamigaki
No relevant relationships to disclose
N. Matsunami
No relevant relationships to disclose
N. Masuda
No relevant relationships to disclose